🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

DuPont (DD) Unit Expands Phytase Product Line In Europe

Published 06/26/2017, 09:06 PM
Updated 07/09/2023, 06:31 AM
US500
-
DOW
-
DD
-
BASFY
-
CC
-
DuPont’s (NYSE:DD) Industrial Biosciences unit has launched Axtra PHY 20000 TPT and Axtra PHY 25000 G in Europe, thereby expanding the product line of its award-winning phytase in the European Union (EU). The fastest-acting phytase enzyme is now available in every desired format to all European animal producers.
Proven to be the most efficacious phytase available in the market today, Axtra PHY has been helping animal producers to reduce their production costs as well as their environmental footprint.
The product starts acting earlier in the digestive tract and destroys phytate and its anti-nutrient effects rapidly. This enables more nutrient uptake in the animal. Axtra PHY enables the release and digestion of beneficial nutrients naturally present in the feed by lowering the impact of phytate. As a result the animal producer can significantly lower their feed cost.
In addition to this, Axtra PHY at 1000 FTU (phytase units) can breakdown more than 90% of dietary phytate and decrease feed conversion ratio by up to 10%.
DuPont has outperformed the Zacks categorized Chemicals-Diversified industry over a year. The company’s shares have rallied 29.3% over this period, compared with the industry’s gain of around 25.8%.
DuPont is well placed to gain from its cost-cutting measures and new product launches. It has numerous new products in its pipeline that should contribute to the top-line growth.
Moreover, the proposed mega-merger with Dow Chemical (NYSE:DOW) is expected to deliver cost synergies of around $3 billion. The companies recently secured the U.S. antitrust clearance for the planned merger and expect the closing of the deal to take place in Aug 2017.
E.I. du Pont de Nemours and Company Price and Consensus
DuPont currently carries a Zacks Rank #2 (Buy).
Other top-ranked companies in the chemical space include BASF SE (OTC:BASFY) and The Chemours Company (NYSE:CC) . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
BASF has expected long-term growth of 8.9%.
Chemours has expected long-term growth of 15.5%.
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.


E.I. du Pont de Nemours and Company (DD): Free Stock Analysis Report

Dow Chemical Company (The) (DOW): Free Stock Analysis Report

BASF SE (BASFY): Free Stock Analysis Report

Chemours Company (The) (CC): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.